Technical Analysis for CLRB - Cellectar Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 1.86 -7.00% -0.14
CLRB closed down 7.0 percent on Monday, May 20, 2019, on 65 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CLRB trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish -7.00%
MACD Bearish Signal Line Cross Bearish -7.00%
Calm After Storm Range Contraction -7.00%

Older signals for CLRB ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Medicine Cancer Clinical Medicine Imaging Oncology Chemotherapy Stem Cells Radiation Antineoplastic Drugs Occupational Safety And Health Radiation Therapy Glioblastoma Targeted Therapy Tomography Solid Tumor Advanced Solid Tumors Ros1
Is CLRB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.76
52 Week Low 1.22
Average Volume 619,472
200-Day Moving Average 2.3441
50-Day Moving Average 2.3382
20-Day Moving Average 2.285
10-Day Moving Average 2.239
Average True Range 0.2753
ADX 24.47
+DI 29.3548
-DI 23.5908
Chandelier Exit (Long, 3 ATRs ) 2.3041
Chandelier Exit (Short, 3 ATRs ) 2.6059
Upper Bollinger Band 2.6557
Lower Bollinger Band 1.9143
Percent B (%b) -0.07
BandWidth 32.446389
MACD Line -0.0528
MACD Signal Line -0.0148
MACD Histogram -0.038
Fundamentals Value
Market Cap 25.89 Million
Num Shares 13.9 Million
EPS -1.13
Price-to-Earnings (P/E) Ratio -1.65
Price-to-Sales 0.00
Price-to-Book 1.98
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.19
Resistance 3 (R3) 2.20 2.10 2.14
Resistance 2 (R2) 2.10 2.02 2.10 2.12
Resistance 1 (R1) 1.98 1.96 1.93 1.97 2.10
Pivot Point 1.88 1.88 1.86 1.88 1.88
Support 1 (S1) 1.76 1.80 1.71 1.75 1.62
Support 2 (S2) 1.66 1.74 1.66 1.60
Support 3 (S3) 1.54 1.66 1.59
Support 4 (S4) 1.53